Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Aclaris Therapeutics鈥� multi-trial disclosures, royalty agreements, and cash runway notes can exceed 250 pages per filing. Pinpointing when a kinase inhibitor enters Phase 2 or tracking executive option exercises shouldn鈥檛 require a doctorate in regulatory science.
Stock Titan鈥檚 AI-powered analysis decodes every Aclaris Therapeutics SEC filing in real time. Need the Aclaris Therapeutics quarterly earnings report 10-Q filing? Our platform highlights R&D spend, liquidity updates, and segment revenue in plain English. Wondering about Aclaris Therapeutics insider trading Form 4 transactions? Receive instant alerts the moment executives buy or sell shares. From the Aclaris Therapeutics annual report 10-K simplified to each Aclaris Therapeutics 8-K material events explained, our summaries surface trial milestones, licensing income, and risk factors in minutes rather than hours.
Investors use these insights to:
- Monitor Aclaris Therapeutics Form 4 insider transactions real-time before pivotal data releases
- Compare quarter-over-quarter R&D burn without wading through accounting footnotes
- Review Aclaris Therapeutics proxy statement executive compensation alongside dilution projections
- Assess cash needs via shelf registration S-3 filings
Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished鈥攏ot filed鈥攕o the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.
The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.
The Vanguard Group filed Amendment No. 2 to a Schedule 13G for CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCCS). As of 30 June 2025 Vanguard reports beneficial ownership of 60,251,392 common shares, representing 9.14 % of CCCS鈥檚 outstanding stock. Vanguard categorises itself as an investment adviser under Rule 13d-1(b).
Voting authority is minimal: 0 shares with sole voting power and 188,758 shares with shared voting power. Dispositive authority is higher, with 59,447,942 shares subject to sole dispositive power and 803,450 shares subject to shared dispositive power. Vanguard certifies that the holdings are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
The filing indicates that Vanguard鈥檚 aggregate position remains passive but confirms that the asset manager continues to hold a stake above the 5 % threshold that triggers Schedule 13G reporting.
On 22 Jul 2025, MillerKnoll (MLKN) General Counsel Jacqueline Hourigan Rice converted 32,018 restricted stock units into common shares at a $0 exercise price (Code M). To cover withholding taxes (Code F), 14,488.129 of those shares were automatically sold at $19.50, resulting in a net increase of 17,529.871 shares.
Following the transactions, Rice directly owns 46,350.1981 MLKN shares versus 28,820.3271 prior to the filing, and still holds 98,747 unvested RSUs (51,699 cliff-vesting FY-24 bonus grant and 47,048 under a three-year schedule). The activity stems from incentive-plan elections rather than open-market trading, and no Rule 10b5-1 trading plan is referenced.
The filing signals continued equity alignment by a senior officer but is largely routine compensation-related and does not, by itself, alter MillerKnoll鈥檚 fundamental outlook.
On 30 June 2025, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed an 8-K solely to furnish an updated corporate overview presentation (Exhibit 99.1) under Item 7.01 鈥� Regulation FD Disclosure. The deck has been posted to the company鈥檚 website and is not deemed 鈥渇iled鈥� for Exchange Act liability or for incorporation by reference. No financial results, strategic transactions, or operational updates were disclosed. All other sections, including Item 9.01, merely list the exhibit numbers, and the filing was signed by CFO Kevin Balthaser.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
What is Aclaris Therapeutics Inc?
What are the core business segments of Aclaris Therapeutics?
What type of conditions does Aclaris target?
How does Aclaris generate revenue?
What differentiates Aclaris in the competitive biopharmaceutical landscape?
What role do strategic partnerships play for Aclaris?
What is the significance of its R&D platform?
How does Aclaris address treatment gaps in its market?
